References
- 1. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cell matter? Blood. 2001;98:2900-2908.
- 2. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood. 1997; 89:2233-2258.
- 3. Jillella AP, Ustun C. What is the optimum number of CD34 peripheral blood stem cells for an autologous transplant? Stem Cells Dev. 2004;13:598-606.10.1089/scd.2004.13.598
- 4. Vose JM, Ho AD, Coiffier B, et al. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma. 2009;50:1412-1421.
- 5. Sancho JM, Morgades M, Grifols JR, et al. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+ cell count to guide pre-emptive or immediate rescue mobilization. Cytotherapy. 2012;14:823-829.10.3109/14653249.2012.681042
- 6. To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118:4530-4540.
- 7. Verfaillie CM. Hematopoietic stem cells for transplantation. Nature Immunology. 2002;3:314-317.10.1038/ni0402-314
- 8. Pozotrigo M, Adel N, Landau L, et al. Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the area of novel therapies: experience at Memorial Sloan Kattering Cancer Center. Bone Marrow Transplantation. 2013;48:1033-1039.
- 9. Worel N, Rosskopf K, Neumeister P, et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion. 2011;51:968-975.10.1111/j.1537-2995.2010.02896.x
- 10. Nur Ozkurt Z, Yegin AZ, Suyan E, et al. Factors Affecting Stem Cell Mobilization for Autologous Hematopoietic Stem Cell Transplantation. Journal of Clinical Apheresis. 2010;25:280-286.